AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9791684 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidole (10 mg/kg body weight in 4 portions for 5 days)
Number of subjects: 802
Study 9791684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 1619184 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Mg oxide) to bring Mg intake to 8 mg/kg body weight/day
Number of subjects: 26
Study 1619184 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 26
Study 6442713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml of 10% Intralipid added to TPN over a period of 12 h (1.8‐2.1 g/kg/day)
Number of subjects: 26
Study 6442713 — intervention group
Group type: COMPARATOR
Intervention: 24h TPN
Number of subjects: 26
Study 28770459 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily for 24 weeks
Number of subjects: 36
Study 28770459 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 29382803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy After Intravenous Alteplase
Number of subjects: 53
Study 29382803 — intervention group
Group type: COMPARATOR
Intervention: Alteplase Alone
Number of subjects: 53
Study 26908003 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal airway based on maxillary incisors to the angle of the mandible
Number of subjects: 113
Study 26908003 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal airway based on corner of the mouth to the angle of the mandible
Number of subjects: 113
Study 25204642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine carbon particles (64 μg/m³; 6.1 ± 0.4 × 10⁵ particles/cm³ for 2 h)
Number of subjects: 12
Study 25204642 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 12
Study 22494567 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 126
Study 19578132 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised diet and exercise plus transdermal testosterone (50 mg once daily)
Number of subjects: 32
Study 19578132 — intervention group
Group type: COMPARATOR
Intervention: Supervised diet and exercise alone
Number of subjects: 32
Study 19578132 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised diet and exercise plus transdermal testosterone
Number of subjects: 32
Study 17538804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil Moisturizing Cream applied twice daily for 15 days on one half of the face
Number of subjects: 20
Study 17538804 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 0.75% gel applied twice daily for at least 15 days
Number of subjects: 20
Study 15045047 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg azithromycin daily (high dose)
Number of subjects: 14
Study 15045047 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg azithromycin twice weekly (low dose)
Number of subjects: 14
Study 15045047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high and low dose azithromycin
Number of subjects: 14
Study 11788107 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-40 mg/day lovastatin
Number of subjects: 1555
Study 11788107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1555
Study 9889712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride baths (30 and 50 g/l)
Number of subjects: 0
Study 9889712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride baths (50 g/l)
Number of subjects: 0
Study 9889712 — intervention group
Group type: COMPARATOR
Intervention: Neutral baths (control group)
Number of subjects: 0
Study 7701577 — intervention group
Group type: COMPARATOR
Intervention: OKT3 (5 mg/d)
Number of subjects: 104
Study 7701577 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F (4 mg/kg/d)
Number of subjects: 104
Study 2707058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized metaproterenol delivered by metered‐dose inhaler (MDI) with a spacer device (Aerochamber)
Number of subjects: 44
Study 2707058 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer delivering metaproterenol
Number of subjects: 44
Study 321727 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (10 mg)
Number of subjects: 41
Study 321727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 30940330 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit feedback and service improvements implemented after July 2007
Number of subjects: 144
Study 30940330 — intervention group
Group type: COMPARATOR
Intervention: Before feedback (2002-2007)
Number of subjects: 144
Study 30940330 — intervention group
Group type: EXPERIMENTAL
Intervention: After feedback (2007-2016)
Number of subjects: 144
Study 30940330 — intervention group
Group type: COMPARATOR
Intervention: Before feedback
Number of subjects: 144
Study 30940330 — intervention group
Group type: EXPERIMENTAL
Intervention: After feedback
Number of subjects: 144
Study 30940330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for patient characteristics after feedback
Number of subjects: 144
Study 28378366 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient-centered communication (E-PCC) style
Number of subjects: 190
Study 28378366 — intervention group
Group type: COMPARATOR
Intervention: Low patient-centered communication (L-PCC) style
Number of subjects: 190
Study 25262244 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based food records
Number of subjects: 18
Study 25262244 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based food records
Number of subjects: 18
Study 25262244 — intervention group
Group type: COMPARATOR
Intervention: Paper-based food records
Number of subjects: 18
Study 25262244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of food record methods
Number of subjects: 18
Study 24063976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin‐IPV
Number of subjects: 0
Study 24063976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin‐IPV adjuvanted with aluminum hydroxide
Number of subjects: 0
Study 24063976 — intervention group
Group type: COMPARATOR
Intervention: Conventional IPV
Number of subjects: 0
Study 21585365 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 30
Study 21585365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19390545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 0
Study 19390545 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 0
Study 16980741 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant agent administered into dental tissues after endo bleaching, cavity filled immediately.
Number of subjects: 169
Study 16980741 — intervention group
Group type: COMPARATOR
Intervention: Control group with tooth cavity left open after endo bleaching, filled after 7 days.
Number of subjects: 169
Study 17129330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, culturally competent intervention in nursing homes
Number of subjects: 12
Study 17129330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 10653232 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 5-mm ports
Number of subjects: 141
Study 10653232 — intervention group
Group type: COMPARATOR
Intervention: Two 10-mm ports and one 5-mm port
Number of subjects: 141
Study 9284858 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day citalopram alone
Number of subjects: 62
Study 9284858 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day citalopram with brief psychosocial intervention
Number of subjects: 62
Study 7890822 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3-0.6 mg/kg/day
Number of subjects: 85
Study 7890822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 85
Study 3337561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation (IORT) combined with external beam irradiation and surgical resection, with or without 5-fluorouracil (5FU)
Number of subjects: 51
Study 30825414 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention using an online social network with weekly posters and active communication with mothers.
Number of subjects: 251
Study 30825414 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention using an online social network.
Number of subjects: 251
Study 30825414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 251
Study 29198191 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate multi-faceted oral health promotion intervention including anticipatory guidance, Motivational Interviewing, health and dental care for mothers during pregnancy and children at 6, 12, and 18 months.
Number of subjects: 454
Study 29198191 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 454
Study 26703489 — intervention group
Group type: COMPARATOR
Intervention: Monarch cartridge C
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch cartridge D
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL power less than 18.0 D
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL power between 18.0 D to 23.5 D
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL power over 23.5 D
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 386
Study 26703489 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL stress fractures
Number of subjects: 386
Study 23782712 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) during ALND
Number of subjects: 280
Study 23782712 — intervention group
Group type: COMPARATOR
Intervention: Standard axillary lymph node dissection (ALND)
Number of subjects: 280
Study 21320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based interventions designed to improve adherence to TUPAC guidelines.
Number of subjects: 0
Study 21320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomised controlled design interventions.
Number of subjects: 0
Study 19811918 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 367
Study 19811918 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + oral cyclophosphamide (RT+C)
Number of subjects: 367
Study 19811918 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide only (C)
Number of subjects: 367
Study 16968397 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg therapy (2 g/kg body weight, monthly for 6 months)
Number of subjects: 6
Study 15164224 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (two types) injected subcutaneously
Number of subjects: 0
Study 15164224 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11001240 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine at a fixed, targeted, weight‐adjusted dose of 2.25 mg x kg(‐1) x day(‐1)
Number of subjects: 110
Study 11001240 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 110
Study 9311358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9311358 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 32
Study 9311358 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 32
Study 8322488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms dose of influenza vaccine
Number of subjects: 79
Study 8322488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms dose of influenza vaccine
Number of subjects: 79
Study 8322488 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms dose of influenza vaccine
Number of subjects: 79
Study 3964359 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi‐Lock polyurethane dressing
Number of subjects: 50
Study 3964359 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazene cream (Silvadene)
Number of subjects: 50
Study 31489472 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiofrequency ablation (SRFA)
Number of subjects: 177
Study 31489472 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 177
Study 30269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary state
Number of subjects: 48
Study 30269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving state
Number of subjects: 48
Study 30269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed bump section
Number of subjects: 48
Study 30269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden stop section
Number of subjects: 48
Study 30269076 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hand cornering section
Number of subjects: 48
Study 27834743 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment arm
Number of subjects: 308
Study 27834743 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 308
Study 27834743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 308
Study 27834743 — intervention group
Group type: EXPERIMENTAL
Intervention: INT occurrence
Number of subjects: 308
Study 24605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg during the extension blinded Conversion Period (n=217)
Number of subjects: 372
Study 24605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg during weeks 1-13 of the extension Maintenance Period (n=181)
Number of subjects: 372
Study 24605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg during the extension
Number of subjects: 372
Study 22672363 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in fibre (>25 g/day)
Number of subjects: 42
Study 22672363 — intervention group
Group type: COMPARATOR
Intervention: Diet low in fibre (<25 g/day)
Number of subjects: 42
Study 22672363 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in fat (% of kcal/day fat intake)
Number of subjects: 42
Study 22672363 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in fibre (g/day)
Number of subjects: 42
Study 22672363 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in carbohydrate (g/day)
Number of subjects: 42
Study 22105257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency endometrial ablation
Number of subjects: 160
Study 22105257 — intervention group
Group type: COMPARATOR
Intervention: Hydrothermablation
Number of subjects: 160
Study 18327813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg orally on Day 1 followed by 80 mg on Days 2-3 (Arm A)
Number of subjects: 75
Study 18327813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg orally on Day 1 and placebo on Days 2-3 (Arm B)
Number of subjects: 75
Study 18327813 — intervention group
Group type: COMPARATOR
Intervention: Placebo on Days 1-3 (Arm C)
Number of subjects: 75
Study 16598822 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional coaching sessions addressing relationship tension
Number of subjects: 29
Study 16598822 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional coaching sessions focusing on togetherness as a couple
Number of subjects: 29
Study 16598822 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional coaching sessions discussing concerns about children
Number of subjects: 29
Study 16598822 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional coaching sessions managing the threat of breast cancer
Number of subjects: 29
Study 14640799 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in caregiving activities by fathers
Number of subjects: 148
Study 14640799 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive relationships reported by grandmothers with young parents
Number of subjects: 148
Study 14640799 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive partner relationships reported by mothers
Number of subjects: 148
Study 14640799 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts to increase paternal involvement
Number of subjects: 148
Study 11113045 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1558
Study 11113045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 11113045 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (within 72 hours of CABG)
Number of subjects: 1558
Study 11113045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (within 72 hours of CABG)
Number of subjects: 1558
Study 11113045 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (after 72 hours of CABG)
Number of subjects: 1558
Study 11113045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 72 hours of CABG)
Number of subjects: 1558
Study 8888665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg daily
Number of subjects: 732
Study 8888665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 732
Study 8888665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU daily
Number of subjects: 732
Study 8888665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 732
Study 1651213 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone fluid
Number of subjects: 0
Study 1651213 — intervention group
Group type: COMPARATOR
Intervention: Long-acting gas
Number of subjects: 0
Study 6173522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 32.5 mg/day
Number of subjects: 12
Study 6173522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 75 mg/day
Number of subjects: 12
Study 6173522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 150 mg/day
Number of subjects: 12
Study 31838486 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 62
Study 31838486 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 62
Study 31838486 — intervention group
Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 62
Study 27995302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tranexamic acid in irrigant fluid
Number of subjects: 400
Study 26547425 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR all-active (1-4 mg/day)
Number of subjects: 333
Study 26547425 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR am (1-4 mg/day in the morning)
Number of subjects: 333
Study 26547425 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR pm (1-4 mg/day in the evening)
Number of subjects: 333
Study 26547425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 23627550 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including mailed CRC screening test kits, low literacy patient education materials, automated phone and text message reminders, in-person follow up calls from a CRC Screening Coordinator, and communication of results to patients.
Number of subjects: 0
Study 23627550 — intervention group
Group type: COMPARATOR
Intervention: Usual care including multiple point‐of‐care interventions (e.g., standing orders, EHR reminders), performance measurement, and financial incentives.
Number of subjects: 0
Study 21565135 — intervention group
Group type: EXPERIMENTAL
Intervention: Suoquan Pill (SQP) 10 g per oral dose twice daily for 8 weeks
Number of subjects: 45
Study 21565135 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Powder (WLP) 10 g per oral dose twice daily for 8 weeks
Number of subjects: 45
Study 21565135 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder 10 g per oral dose twice daily for 8 weeks
Number of subjects: 45
Study 21565135 — intervention group
Group type: EXPERIMENTAL
Intervention: Suoquan Pill (SQP) and Wuling Powder (WLP)
Number of subjects: 45
Study 19276670 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy consisting of 2‐3 cycles of cisplatin and 5‐Fluorouracil followed by low dose weekly cisplatin based chemoradiotherapy (treatment arm: n = 48)
Number of subjects: 105
Study 19276670 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy only (control arm: n = 57)
Number of subjects: 105
Study 17888186 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL/day of red wine for two weeks
Number of subjects: 40
Study 17888186 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstained from alcohol for two weeks)
Number of subjects: 40
Study 15530198 — intervention group
Group type: EXPERIMENTAL
Intervention: High prior knowledge (HiPK) with well-structured texts
Number of subjects: 195
Study 15530198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low prior knowledge (LoPK) with well-structured texts
Number of subjects: 195
Study 15530198 — intervention group
Group type: EXPERIMENTAL
Intervention: High prior knowledge (HiPK) with less structured texts
Number of subjects: 195
Study 15530198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low prior knowledge (LoPK) with less structured texts
Number of subjects: 195
Study 11322056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Apraclonidin eye drops applied twice daily for 8 days
Number of subjects: 10
Study 11322056 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication (0.9% NaCI) applied according to the same protocol
Number of subjects: 10
Study 9063761 — intervention group
Group type: COMPARATOR
Intervention: 19.3% glucose polymer solution (C trial)
Number of subjects: 17
Study 9063761 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% glucose polymer solution (D trial)
Number of subjects: 17
Study 7938563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 100
Study 7938563 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 100
Study 7938563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3296238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertransverse fusion with internal fixation
Number of subjects: 69
Study 3296238 — intervention group
Group type: COMPARATOR
Intervention: No fusion
Number of subjects: 69
Study 31548616 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated BP measurements
Number of subjects: 172